{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T19:13:14Z","timestamp":1790190794532,"version":"4.1.0"},"reference-count":86,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2020,2,21]],"date-time":"2020-02-21T00:00:00Z","timestamp":1582243200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100007393","name":"Association Fran\u00e7aise contre les Myopathies","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007393","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"DOI":"10.3389\/fimmu.2020.00240","type":"journal-article","created":{"date-parts":[[2020,2,21]],"date-time":"2020-02-21T11:53:11Z","timestamp":1582285991000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":46,"title":["New Approaches to Targeting B Cells for Myasthenia Gravis Therapy"],"prefix":"10.3389","volume":"11","author":[{"given":"Ruksana","family":"Huda","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2020,2,21]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"E671","DOI":"10.3390\/cells8070671","article-title":"Myasthenia gravis: pathogenic effects of autoantibodies on neuromuscular architecture","volume":"8","author":"Koneczny","year":"2019","journal-title":"Cells"},{"key":"B2","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1038\/s41572-019-0079-y","article-title":"Myasthenia gravis","volume":"5","author":"Gilhus","year":"2019","journal-title":"Nat Rev Dis Primers"},{"key":"B3","doi-asserted-by":"publisher","first-page":"1756286419832242","DOI":"10.1177\/1756286419832242","article-title":"Understanding the burden of refractory myasthenia gravis","volume":"12","author":"Schneider-Gold","year":"2019","journal-title":"Ther Adv Neurol Disord"},{"key":"B4","doi-asserted-by":"publisher","first-page":"265","DOI":"10.3233\/JND-170294","article-title":"New pathways and therapeutic targets in autoimmune myasthenia gravis","volume":"5","author":"Behin","year":"2018","journal-title":"J Neuromuscul Dis"},{"key":"B5","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1038\/s41582-018-0110-z","article-title":"Immunotherapy in myasthenia gravis in the era of biologics","volume":"15","author":"Dalakas","year":"2019","journal-title":"Nat Rev Neurol"},{"key":"B6","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1006\/clim.1999.4807","article-title":"Animal models of myasthenia gravis","volume":"94","author":"Christadoss","year":"2000","journal-title":"Clin Immunol"},{"key":"B7","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/j.jaut.2014.06.003","article-title":"Experimental autoimmune myasthenia gravis (EAMG): from immunochemical characterization to therapeutic approaches","volume":"54","author":"Fuchs","year":"2014","journal-title":"J Autoimmun"},{"key":"B8","doi-asserted-by":"publisher","first-page":"827254","DOI":"10.1155\/2013\/827254","article-title":"B lymphocytes: development, tolerance, and their role in autoimmunity-focus on systemic lupus erythematosus","volume":"2013","author":"Tob\u00f3n","year":"2013","journal-title":"Autoimmune Dis"},{"key":"B9","doi-asserted-by":"publisher","first-page":"835","DOI":"10.3389\/fimmu.2018.00835","article-title":"Targeting B cells and plasma cells in autoimmune diseases","volume":"9","author":"Hofmann","year":"2018","journal-title":"Front Immunol"},{"key":"B10","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1084\/jem.20011626","article-title":"Short-lived and long-lived bone marrow plasma cells are derived from a novel precursor population","volume":"195","author":"O'Connor","year":"2002","journal-title":"J Exp Med"},{"key":"B11","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1146\/annurev-immunol-042617-053214","article-title":"Tissue-resident T cells and other resident leukocytes","volume":"37","author":"Masopust","year":"2019","journal-title":"Annu Rev Immunol"},{"key":"B12","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1038\/s41590-018-0260-6","article-title":"The establishment of resident memory B cells in the lung requires local antigen encounter","volume":"20","author":"Allie","year":"2019","journal-title":"Nat Immunol"},{"key":"B13","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1586\/eci.12.34","article-title":"Muscle autoantibodies in myasthenia gravis: beyond diagnosis?","volume":"8","author":"Meriggioli","year":"2012","journal-title":"Expert Rev Clin Immunol"},{"key":"B14","doi-asserted-by":"publisher","first-page":"3361","DOI":"10.2169\/internalmedicine.55.7030","article-title":"Double seronegative myasthenia gravis with Anti-LRP4 antibodies presenting with dropped head and acute respiratory insufficiency","volume":"55","author":"Beck","year":"2016","journal-title":"Intern Med"},{"key":"B15","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1111\/j.1749-6632.2012.06783.x","article-title":"The role of complement in experimental autoimmune myasthenia gravis","volume":"1274","author":"Kusner","year":"2012","journal-title":"Ann NY Acad Sci"},{"key":"B16","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1515\/revneuro-2014-0021","article-title":"Targeting complement system to treat myasthenia gravis","volume":"4","author":"Huda","year":"2014","journal-title":"Rev Neurosci"},{"key":"B17","doi-asserted-by":"publisher","first-page":"F1000","DOI":"10.12688\/f1000research.8206.1","article-title":"Pathogenesis of myasthenia gravis: update on disease types, models, and mechanisms","volume":"5","author":"Phillips","year":"2016","journal-title":"F1000Res"},{"key":"B18","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1016\/j.jneuroim.2013.09.006","article-title":"Disturbed B cell subpopulations and increased plasma cells in myasthenia gravis patients","volume":"264","author":"Kohler","year":"2013","journal-title":"J Neuroimmunol"},{"key":"B19","doi-asserted-by":"publisher","first-page":"1583","DOI":"10.1093\/intimm\/13.12.1583","article-title":"Role of B cells as antigen-presenting cells in vivo revisited: antigen-specific B cells are essential for T cell expansion in lymph nodes and for systemic T cell responses to low antigen concentrations","volume":"13","author":"Rivera","year":"2001","journal-title":"Int Immunol"},{"key":"B20","doi-asserted-by":"publisher","first-page":"4555","DOI":"10.4049\/jimmunol.1502033","article-title":"CD nomenclature 2015: human leukocyte differentiation antigen workshops as a driving force in immunology","volume":"195","author":"Engel","year":"2015","journal-title":"J Immunol"},{"key":"B21","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1016\/j.imlet.2010.09.019","article-title":"New B-cell CD molecules","volume":"134","author":"Matesanz-Isabel","year":"2011","journal-title":"Immunol Lett"},{"key":"B22","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1007\/978-1-61779-974-7_30","article-title":"Fc engineering: design, expression, and functional characterization of antibody variants with improved effector function","volume":"907","author":"Derer","year":"2012","journal-title":"Methods Mol Biol"},{"key":"B23","doi-asserted-by":"publisher","first-page":"2450","DOI":"10.3389\/fimmu.2018.02450","article-title":"Editorial: antibody fc engineering: towards better therapeutics","volume":"9","author":"Lei","year":"2018","journal-title":"Front Immunol"},{"key":"B24","doi-asserted-by":"publisher","first-page":"85","DOI":"10.2174\/1574884712666170809124728","article-title":"Monoclonal antibodies: a review","volume":"13","author":"Singh","year":"2018","journal-title":"Curr Clin Pharmacol"},{"key":"B25","doi-asserted-by":"publisher","first-page":"898","DOI":"10.1080\/19420862.2017.1341029","article-title":"Changes to international nonproprietary names for antibody therapeutics 2017 and beyond: of mice, men and more","volume":"9","author":"Parren","year":"2017","journal-title":"MAbs"},{"key":"B26","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1002\/acn3.314","article-title":"Rituximab in refractory myasthenia gravis: a prospective, open-label study with long-term follow-up","volume":"3","author":"Anderson","year":"2016","journal-title":"Ann Clin Transl Neurol"},{"key":"B27","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1002\/mus.25973","article-title":"B cells in the pathophysiology of myasthenia gravis","volume":"57","author":"Yi","year":"2018","journal-title":"Muscle Nerve"},{"key":"B28","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1111\/nyas.13535","article-title":"Mechanisms underlying B cell immune dysregulation and autoantibody production in MuSK myasthenia gravis","volume":"1412","author":"Stathopoulos","year":"2018","journal-title":"Ann NY Acad Sci"},{"key":"B29","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1016\/j.jneuroim.2019.05.004","article-title":"Effect of low-dose rituximab treatment on T- and B-cell lymphocyte imbalance in refractory myasthenia gravis","volume":"332","author":"Jing","year":"2019","journal-title":"J Neuroimmunol"},{"key":"B30","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1007\/s00415-019-09191-6","article-title":"High efficacy of rituximab for myasthenia gravis: a comprehensive nationwide study in Austria","volume":"266","author":"Topakian","year":"2019","journal-title":"J Neurol"},{"key":"B31","doi-asserted-by":"publisher","first-page":"118","DOI":"10.5152\/eurjrheum.2018.17096","article-title":"Outcomes of rituximab therapy in refractory lupus: a meta-analysis","volume":"5","author":"Alshaiki","year":"2018","journal-title":"Eur J Rheumatol"},{"key":"B32","doi-asserted-by":"publisher","first-page":"87","DOI":"10.2147\/DDDT.S41645","article-title":"Rituximab for the treatment of rheumatoid arthritis: an update","volume":"8","author":"Mok","year":"2013","journal-title":"Drug Des Devel Ther"},{"key":"B33","doi-asserted-by":"publisher","first-page":"S0169","DOI":"10.1016\/j.addr.2018.12.005","article-title":"Targeting the CD40-CD40L pathway in autoimmune diseases: Humoral immunity and beyond","volume":"13","author":"Karnell","year":"2018","journal-title":"Adv Drug Deliv Rev"},{"key":"B34","doi-asserted-by":"publisher","first-page":"2895","DOI":"10.1111\/ajt.14872","article-title":"Characterization of the in vitro and in vivo properties of CFZ533, a blocking and non-depleting anti-CD40 monoclonal antibody","volume":"18","author":"Ristov","year":"2018","journal-title":"Am J Transplant"},{"key":"B35","doi-asserted-by":"publisher","first-page":"422","DOI":"10.4161\/mabs.3.5.16983","article-title":"Neonatal Fc receptor and IgG-based therapeutics","volume":"3","author":"Kuo","year":"2011","journal-title":"MAbs"},{"key":"B36","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.1212\/WNL.0000000000007605","article-title":"Efgartigimod: a novel antibody depletion therapy in myasthenia gravis","volume":"92","author":"Guidon","year":"2019","journal-title":"Neurology"},{"key":"B37","doi-asserted-by":"publisher","first-page":"4372","DOI":"10.1172\/JCI97911","article-title":"Neonatal Fc receptor antagonist efgartigimod safely and sustainably reduces IgGs in humans","volume":"128","author":"Ulrichts","year":"2018","journal-title":"J Clin Invest"},{"key":"B38","doi-asserted-by":"publisher","first-page":"e2661","DOI":"10.1212\/WNL.0000000000007600","article-title":"Efgartigimod MG study group","volume":"92","author":"Howard","year":"2019","journal-title":"Neurology"},{"key":"B39","doi-asserted-by":"publisher","first-page":"102366","DOI":"10.1016\/j.autrev.2019.102366","article-title":"Next-generation Fc receptor-targeting biologics for autoimmune diseases","volume":"18","author":"Zuercher","year":"2019","journal-title":"Autoimmun Rev"},{"key":"B40","doi-asserted-by":"publisher","first-page":"1301","DOI":"10.4155\/fmc-2017-0057","article-title":"Antibody and antibody mimetic immunotherapeutics","volume":"9","author":"Ta","year":"2017","journal-title":"Future Med Chem"},{"key":"B41","doi-asserted-by":"publisher","first-page":"885","DOI":"10.1016\/j.autrev.2013.03.011","article-title":"Ectopic germinal centers, BAFF and anti-B-cell therapy in myasthenia gravis","volume":"12","author":"Berrih-Aknin","year":"2013","journal-title":"Autoimmun Rev"},{"key":"B42","doi-asserted-by":"publisher","first-page":"e1425","DOI":"10.1212\/WNL.0000000000005323","article-title":"Randomized study of adjunctive belimumab in participants with generalized myasthenia gravis","volume":"90","author":"Hewett","year":"2018","journal-title":"Neurology"},{"key":"B43","doi-asserted-by":"publisher","first-page":"e024523","DOI":"10.1136\/bmjopen-2018-024523","article-title":"Bortezomib in antibody-mediated autoimmune diseases (TAVAB): study protocol for a unicentric, non-randomised, non-placebo controlled trial","volume":"9","author":"Kohler","year":"2019","journal-title":"BMJ Open"},{"key":"B44","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1177\/1756285617721093","article-title":"Bortezomib in severe MuSK-antibody positive myasthenia gravis: first clinical experience","volume":"10","author":"Schneider-Gold","year":"2017","journal-title":"Ther Adv Neurol Disord"},{"key":"B45","doi-asserted-by":"publisher","first-page":"2503","DOI":"10.4049\/jimmunol.1002539","article-title":"Proteasome inhibition with bortezomib depletes plasma cells and autoantibodies in experimental autoimmune myasthenia gravis","volume":"186","author":"Gomez","year":"2011","journal-title":"J Immunol"},{"key":"B46","doi-asserted-by":"publisher","first-page":"1055","DOI":"10.4049\/jimmunol.1301555","article-title":"Proteasome inhibition with bortezomib depletes plasma cells and specific autoantibody production in primary thymic cell cultures from early-onset myasthenia gravis patients","volume":"193","author":"Gomez","year":"2014","journal-title":"J Immunol"},{"key":"B47","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1124\/pr.117.015370","article-title":"A practical review of proteasome pharmacology","volume":"71","author":"Thibaudeau","year":"2019","journal-title":"Pharmacol Rev"},{"key":"B48","doi-asserted-by":"publisher","first-page":"6867","DOI":"10.1038\/sj.onc.1203219","article-title":"How NF-kappaB is activated: the role of the IkappaB kinase (IKK) complex","volume":"18","author":"Karin","year":"1999","journal-title":"Oncogene"},{"key":"B49","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1016\/j.jaut.2011.05.006","article-title":"Complement and cytokine based therapeutic strategies in myasthenia gravis","volume":"37","author":"T\u00fcz\u00fcn","year":"2011","journal-title":"J Autoimmun"},{"key":"B50","doi-asserted-by":"publisher","first-page":"1077","DOI":"10.4049\/jimmunol.169.2.1077","article-title":"Resistance to experimental autoimmune myasthenia gravis in IL-6-deficient mice is associated with reduced germinal center formation and C3 production","volume":"2","author":"Deng","year":"2002","journal-title":"J Immunol"},{"key":"B51","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1016\/j.jaut.2010.12.001","article-title":"Blocking of IL-6 suppresses experimental autoimmune myasthenia gravis","volume":"36","author":"Aricha","year":"2011","journal-title":"J Autoimmun"},{"key":"B52","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1016\/j.nmd.2017.03.007","article-title":"Beneficial effect of tocilizumab in myasthenia gravis refractory to rituximab","volume":"27","author":"Jonsson","year":"2017","journal-title":"Neuromuscul Disord"},{"key":"B53","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1016\/j.jaut.2005.01.013","article-title":"Myasthenia gravis patients with low plasma IL-6 and IFN-gamma benefit from etanercept treatment","volume":"24","author":"T\u00fcz\u00fcn","year":"2005","journal-title":"J Autoimmun"},{"key":"B54","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1006\/jaut.2002.0618","article-title":"Anti-TNF-\u03b1 antibodies suppress the development of experimental autoimmune myasthenia gravis","volume":"19","author":"Duan","year":"2002","journal-title":"J Autoimmun"},{"key":"B55","doi-asserted-by":"publisher","first-page":"866","DOI":"10.1002\/mus.21280","article-title":"Myasthenia gravis associated with etanercept therapy","volume":"39","author":"Fee","year":"2009","journal-title":"Muscle Nerve"},{"key":"B56","first-page":"537","article-title":"Reactivation of tuberculosis during treatment with inhibitors of TNF","volume":"68","author":"Miossec","year":"2018","journal-title":"Rev Prat"},{"key":"B57","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1002\/art.27271","article-title":"Tumor necrosis factor neutralization results in disseminated disease in acute and latent Mycobacterium tuberculosis infection with normal granuloma structure in a cynomolgus macaque model","volume":"62","author":"Lin","year":"2010","journal-title":"Arthritis Rheum"},{"key":"B58","doi-asserted-by":"publisher","first-page":"1593","DOI":"10.2147\/DDDT.S100302","article-title":"Profile of sarilumab and its potential in the treatment of rheumatoid arthritis","volume":"11","author":"Raimondo","year":"2017","journal-title":"Drug Des Devel Ther"},{"key":"B59","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1136\/annrheumdis-2014-206090","article-title":"A Phase II study of the efficacy and safety of rontalizumab (rhuMAb interferon-\u03b1) in patients with systemic lupus erythematosus (ROSE)","volume":"75","author":"Kalunian","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"B60","doi-asserted-by":"crossref","first-page":"5675","DOI":"10.4049\/jimmunol.157.12.5675","article-title":"IFN-alpha therapy is effective in suppressing the clinical experimental myasthenia gravis","volume":"157","author":"Deng","year":"1996","journal-title":"J Immunol"},{"key":"B61","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1097\/CND.0b013e318285257f","article-title":"Pegylated interferon induced myasthenia crisis\u2013a case report","volume":"14","author":"Congeni","year":"2013","journal-title":"J Clin Neuromuscul Dis"},{"key":"B62","doi-asserted-by":"publisher","first-page":"e3782","DOI":"10.1097\/MD.0000000000003782","article-title":"Myasthenia crisis induced by pegylated-interferon in patient with chronic hepatitis c: a case report","volume":"95","author":"Baik","year":"2016","journal-title":"Medicine"},{"key":"B63","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1016\/j.jneuroim.2017.08.005","article-title":"ONX-0914, a selective inhibitor of immunoproteasome, ameliorates experimental autoimmune myasthenia gravis by modulating humoral response","volume":"311","author":"Liu","year":"2017","journal-title":"J Neuroimmunol"},{"key":"B64","doi-asserted-by":"publisher","first-page":"39716","DOI":"10.1038\/srep39716","article-title":"Profile of upregulated inflammatory proteins in sera of myasthenia gravis patients","volume":"7","author":"Molin","year":"2017","journal-title":"Sci Rep"},{"key":"B65","doi-asserted-by":"publisher","first-page":"5324","DOI":"10.4049\/jimmunol.174.9.5324","article-title":"Overexpression of IFN-induced protein 10 and its receptor CXCR3 in myasthenia gravis","volume":"174","author":"Feferman","year":"2005","journal-title":"J Immunol"},{"key":"B66","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1016\/j.jneuroim.2009.01.021","article-title":"Suppression of experimental autoimmune myasthenia gravis by inhibiting the signaling between IFN-gamma inducible protein 10 (IP-10) and its receptor CXCR3","volume":"209","author":"Feferman","year":"2009","journal-title":"J Neuroimmunol"},{"key":"B67","doi-asserted-by":"publisher","first-page":"7550","DOI":"10.18632\/oncotarget.6885","article-title":"Novel CXCL13 transgenic mouse: inflammation drives pathogenic effect of CXCL13 in experimental myasthenia gravis","volume":"7","author":"Weiss","year":"2016","journal-title":"Oncotarget."},{"key":"B68","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1111\/imm.12347","article-title":"Silencing miR-146a influences B cells and ameliorates experimental autoimmune myasthenia gravis","volume":"144","author":"Zhang","year":"2015","journal-title":"Immunology."},{"key":"B69","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1111\/nyas.13510","article-title":"Circulating microRNAs as potential biomarkers in myasthenia gravis patients","volume":"1412","author":"Punga","year":"2018","journal-title":"Ann NY Acad Sci"},{"key":"B70","doi-asserted-by":"publisher","first-page":"8165","DOI":"10.1007\/s00253-017-8557-1","article-title":"Development of humanized scFv antibody fragment(s) that targets and blocks specific HLA alleles linked to myasthenia gravis","volume":"101","author":"Ayyar","year":"2017","journal-title":"Appl Microbiol Biotechnol."},{"key":"B71","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/j.jaut.2015.09.005","article-title":"Suppression of experimental autoimmune myasthenia gravis by autologous T regulatory cells","volume":"67","author":"Aricha","year":"2016","journal-title":"J Autoimmun."},{"key":"B72","doi-asserted-by":"publisher","first-page":"1133","DOI":"10.3389\/fimmu.2017.01133","article-title":"A novel approach to reinstating tolerance in experimental autoimmune myasthenia gravis using a targeted fusion protein, mCTA1-T146","volume":"8","author":"Consonni","year":"2017","journal-title":"Front Immunol"},{"key":"B73","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1016\/S0165-5728(00)00395-7","article-title":"Mechanism of nasal tolerance induced by a recombinant fragment of acetylcholine receptor for treatment of experimental myasthenia gravis","volume":"111","author":"Im","year":"2000","journal-title":"J Neuroimmunol"},{"key":"B74","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1016\/j.clim.2017.01.005","article-title":"High-dose BAFF receptor specific mAb-siRNA conjugate generates Fas-expressing B cells in lymph nodes and high-affinity serum autoantibody in a myasthenia mouse model","volume":"176","author":"Ibtehaj","year":"2017","journal-title":"Clin Immunol"},{"key":"B75","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/j.molimm.2016.03.002","article-title":"Fc-galactosylation modulates antibody-dependent cellular cytotoxicity of therapeutic antibodies","volume":"73","author":"Thomann","year":"2016","journal-title":"Mol Immunol"},{"key":"B76","doi-asserted-by":"publisher","first-page":"12023","DOI":"10.1073\/pnas.1812833115","article-title":"Site-selective chemoenzymatic glycoengineering of Fab and Fc glycans of a therapeutic antibody","volume":"115","author":"Giddens","year":"2018","journal-title":"Proc Natl Acad Sci USA"},{"key":"B77","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1016\/j.expneurol.2015.03.010","article-title":"Standardization of the experimental autoimmune myasthenia gravis (EAMG) model by immunization of rats with torpedo californica acetylcholine receptors\u2013recommendations for methods and experimental designs","volume":"270","author":"Losen","year":"2015","journal-title":"Exp Neurol"},{"key":"B78","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.expneurol.2015.02.025","article-title":"Guidelines for pre-clinical assessment of the acetylcholine receptor\u2013specific passive transfer myasthenia gravis model-Recommendations for methods and experimental designs","volume":"270","author":"Kusner","year":"2015","journal-title":"Exp Neurol"},{"key":"B79","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.expneurol.2014.12.013","article-title":"Guidelines for pre-clinical animal and cellular models of MuSK-myasthenia gravis","volume":"270","author":"Phillips","year":"2015","journal-title":"Exp Neurol"},{"key":"B80","doi-asserted-by":"publisher","first-page":"53","DOI":"10.2147\/IJGM.S88552","article-title":"Animal models of myasthenia gravis: utility and limitations","volume":"9","author":"Mantegazza","year":"2016","journal-title":"Int J Gen Med"},{"key":"B81","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1016\/j.ejca.2018.09.033","article-title":"Myositis and neuromuscular side-effects induced by immune checkpoint inhibitors","volume":"106","author":"Moreira","year":"2019","journal-title":"Eur J Cancer"},{"key":"B82","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1016\/j.it.2019.04.002","article-title":"Adverse events following cancer immunotherapy: obstacles and opportunities","volume":"40","author":"Pauken","year":"2019","journal-title":"Trends Immunol"},{"key":"B83","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1186\/s40425-019-0617-x","article-title":"Neurologic toxicity associated with immune checkpoint inhibitors: a pharmacovigilance study","volume":"7","author":"Johnson","year":"2019","journal-title":"J Immunother Cancer"},{"key":"B84","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1016\/j.ejca.2017.05.041","article-title":"Myasthenia gravis: an emerging toxicity of immune checkpoint inhibitors","volume":"82","author":"Makarious","year":"2017","journal-title":"Eur J Cancer"},{"key":"B85","doi-asserted-by":"publisher","first-page":"169","DOI":"10.3233\/JND-170219","article-title":"Severe exacerbation of myasthenia gravis associated with checkpoint inhibitor immunotherapy","volume":"4","author":"Cooper","year":"2017","journal-title":"J Neuromuscul Dis"},{"key":"B86","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1097\/CJI.0000000000000278","article-title":"Myasthenia gravis induced by immune checkpoint inhibitors","volume":"42","author":"Becquart","year":"2019","journal-title":"J Immunother"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fimmu.2020.00240\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,27]],"date-time":"2023-09-27T09:43:22Z","timestamp":1695807802000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fimmu.2020.00240\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,2,21]]},"references-count":86,"alternative-id":["10.3389\/fimmu.2020.00240"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2020.00240","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,2,21]]},"article-number":"240"}}